Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors

Abstract

"Progression-free survival (PFS) is increasingly used as an important and even a primary endpoint in randomized cancer clinical trials in the evaluation of patients with solid tumors for both practical and clinical considerations. Although in its simplest form, PFS is the time from randomization to a predefined endpoint, there are many factors that can influence the exact moment of when disease progression is recorded. In this overview, we review the circumstances that can devalue the use of PFS as a primary endpoint and attempt to provide a pathway for a future desired state when PFS will become not just a secondary alternative to overall survival but rather an endpoint of choice."

Articles citing this article

• Modeling the Relationship between Progression-Free Survival and Overall Survival: The Phase II/III Trial Clin. Cancer Res. May 15, 2013 19:2646-2656
  • Abstract
• The Imaging Viewpoint: How Imaging Affects Determination of Progression-Free Survival Clin. Cancer Res. May 15, 2013 19:2621-2628
  • Abstract